Lymphangioleiomyomatosis: Difference between revisions

(Created page with "Lymphangioleiomyomatosis (LAM) is a rare, progressive, low-grade neoplastic lung disease characterized by infiltration of abnormal smooth muscle-like cells (LAM cells) into the lung parenchyma, lymphatics, and blood vessels, resulting in '''diffuse thin-walled cystic destruction''' of both lungs.<ref name="StatPearls">Lymphangioleiomyomatosis. ''StatPearls''. NCBI Bookshelf. Updated June 2023.</ref> It almost exclusively affects '''women of childbearing age''' (mean diag...")
 
(Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential and SOB DDX templates)
Line 1: Line 1:
Lymphangioleiomyomatosis (LAM) is a rare, progressive, low-grade neoplastic lung disease characterized by infiltration of abnormal smooth muscle-like cells (LAM cells) into the lung parenchyma, lymphatics, and blood vessels, resulting in '''diffuse thin-walled cystic destruction''' of both lungs.<ref name="StatPearls">Lymphangioleiomyomatosis. ''StatPearls''. NCBI Bookshelf. Updated June 2023.</ref> It almost exclusively affects '''women of childbearing age''' (mean diagnosis ~35 years). LAM cells harbor mutations in '''tuberous sclerosis complex (TSC)''' genes causing constitutive activation of the '''mTOR pathway'''.<ref name="Lancet">McCormack FX, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. ''Lancet Respir Med''. 2021.</ref> ED physicians will most commonly encounter LAM patients presenting with '''recurrent spontaneous [[pneumothorax]]''', '''chylous pleural effusion''', or progressive dyspnea — and the diagnosis may not yet be established.
==Background==
==Background==
*Lymphangioleiomyomatosis (LAM) is a rare, progressive, low-grade neoplastic lung disease characterized by infiltration of abnormal smooth muscle-like cells (LAM cells) into the lung parenchyma, lymphatics, and blood vessels, resulting in diffuse thin-walled cystic destruction of both lungs.<ref name="StatPearls">Lymphangioleiomyomatosis. ''StatPearls''. NCBI Bookshelf. Updated June 2023.</ref> It almost exclusively affects women of childbearing age (mean diagnosis ~35 years).
*LAM cells harbor mutations in tuberous sclerosis complex (TSC) genes causing constitutive activation of the mTOR pathway.<ref name="Lancet">McCormack FX, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. ''Lancet Respir Med''. 2021.</ref> ED physicians will most commonly encounter LAM patients presenting with recurrent spontaneous [[pneumothorax]], chylous pleural effusion, or progressive dyspnea — and the diagnosis may not yet be established.
*LAM occurs in two forms:<ref name="StatPearls"/>
*LAM occurs in two forms:<ref name="StatPearls"/>
**'''Sporadic LAM (S-LAM):''' Somatic TSC2 mutations; ~3.4–7.8 per million women; no family inheritance
** Sporadic LAM (S-LAM): Somatic TSC2 mutations; ~3.4–7.8 per million women; no family inheritance
**'''TSC-associated LAM (TSC-LAM):''' 30–40% of women with tuberous sclerosis develop LAM; autosomal dominant TSC1 or TSC2 germline mutations
** TSC-associated LAM (TSC-LAM): 30–40% of women with tuberous sclerosis develop LAM; autosomal dominant TSC1 or TSC2 germline mutations
*LAM cells are neoplastic smooth muscle-like cells that express smooth muscle actin, '''HMB-45''' (melanocytic marker — key for pathologic diagnosis), and estrogen/progesterone receptors<ref name="ERS2010">Johnson SR, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. ''Eur Respir J''. 2010;35(1):14-26.</ref>
*LAM cells are neoplastic smooth muscle-like cells that express smooth muscle actin, '''HMB-45''' (melanocytic marker — key for pathologic diagnosis), and estrogen/progesterone receptors<ref name="ERS2010">Johnson SR, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. ''Eur Respir J''. 2010;35(1):14-26.</ref>
*'''Estrogen dependence:''' LAM almost exclusively affects premenopausal women; may accelerate during pregnancy and with exogenous estrogen; decelerates after menopause<ref name="StatPearls"/>
* Estrogen dependence: LAM almost exclusively affects premenopausal women; may accelerate during pregnancy and with exogenous estrogen; decelerates after menopause<ref name="StatPearls"/>
*'''Pathogenesis:''' TSC gene mutations → loss of hamartin/tuberin tumor suppressor complex → constitutive mTORC1 activation → uncontrolled cell proliferation, lymphangiogenesis, and cystic lung destruction<ref name="Lancet"/>
* Pathogenesis: TSC gene mutations → loss of hamartin/tuberin tumor suppressor complex → constitutive mTORC1 activation → uncontrolled cell proliferation, lymphangiogenesis, and cystic lung destruction<ref name="Lancet"/>
*LAM cells metastasize via the lymphatics (LAM is considered a low-grade metastasizing neoplasm with likely uterine origin)<ref name="Lancet"/>
*LAM cells metastasize via the lymphatics (LAM is considered a low-grade metastasizing neoplasm with likely uterine origin)<ref name="Lancet"/>
*Proliferation of LAM cells obstructs bronchioles (→ air trapping, bullae, [[pneumothorax]]), lymphatics (→ chylous effusions), and venules (→ hemoptysis)<ref name="Medscape">Lymphangioleiomyomatosis. ''Medscape/eMedicine''. Updated 2024.</ref>
*Proliferation of LAM cells obstructs bronchioles (→ air trapping, bullae, [[pneumothorax]]), lymphatics (→ chylous effusions), and venules (→ hemoptysis)<ref name="Medscape">Lymphangioleiomyomatosis. ''Medscape/eMedicine''. Updated 2024.</ref>
*'''Extrapulmonary manifestations:'''
* Extrapulmonary manifestations:
**'''Renal angiomyolipomas (AML):''' Present in ~30–40% of S-LAM and ~80% of TSC-LAM; benign fat-containing tumors; may hemorrhage (especially >4 cm)<ref name="ERS2010"/>
** Renal angiomyolipomas (AML): Present in ~30–40% of S-LAM and ~80% of TSC-LAM; benign fat-containing tumors; may hemorrhage (especially >4 cm)<ref name="ERS2010"/>
**'''Lymphangioleiomyomas:''' Cystic masses of the axial lymphatics; abdominopelvic lymphadenopathy
** Lymphangioleiomyomas: Cystic masses of the axial lymphatics; abdominopelvic lymphadenopathy
**'''Chylous effusions:''' Chylothorax (~20%) and/or chylous ascites from lymphatic obstruction<ref name="LAMFound">LAM Management. The LAM Foundation. Updated October 2023.</ref>
** Chylous effusions: Chylothorax (~20%) and/or chylous ascites from lymphatic obstruction<ref name="LAMFound">LAM Management. The LAM Foundation. Updated October 2023.</ref>
**Increased frequency of meningiomas<ref name="ERS2010"/>
**Increased frequency of meningiomas<ref name="ERS2010"/>
*'''Epidemiology:''' ~3.4–7.8 per million women (sporadic LAM); prevalence likely underestimated due to delayed diagnosis (average 5–6 years from symptom onset)<ref name="StatPearls"/>
* Epidemiology: ~3.4–7.8 per million women (sporadic LAM); prevalence likely underestimated due to delayed diagnosis (average 5–6 years from symptom onset)<ref name="StatPearls"/>
*FEV1 declines at ~75–118 mL/year in untreated patients<ref name="MILES">McCormack FX, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. ''N Engl J Med''. 2011;364(17):1595-1606.</ref>
*FEV1 declines at ~75–118 mL/year in untreated patients<ref name="MILES">McCormack FX, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. ''N Engl J Med''. 2011;364(17):1595-1606.</ref>
*>90% 10-year survival with modern management<ref name="ClevelandClinic">Lymphangioleiomyomatosis (LAM). Cleveland Clinic. Updated December 2025.</ref>
*>90% 10-year survival with modern management<ref name="ClevelandClinic">Lymphangioleiomyomatosis (LAM). Cleveland Clinic. Updated December 2025.</ref>


==Clinical Features==
==Clinical Features==
*'''Progressive exertional dyspnea''' — the most common symptom; insidious onset; often attributed to [[asthma]] or deconditioning for years before diagnosis<ref name="StatPearls"/>
* Progressive exertional dyspnea — the most common symptom; insidious onset; often attributed to [[asthma]] or deconditioning for years before diagnosis<ref name="StatPearls"/>
*'''Recurrent spontaneous [[pneumothorax]]:'''<ref name="Lancet"/>
* Recurrent spontaneous [[pneumothorax]]:<ref name="Lancet"/>
**Occurs in ~66% of LAM patients during their lifetime
**Occurs in ~66% of LAM patients during their lifetime
**'''Presenting manifestation in ~25%''' of patients — this is often how LAM is first diagnosed
** Presenting manifestation in ~25% of patients — this is often how LAM is first diagnosed
**'''Recurrence rate >70%''' if managed conservatively (observation/aspiration alone)
** Recurrence rate >70% if managed conservatively (observation/aspiration alone)
**Lifetime average of 3–4 pneumothoraces per patient
**Lifetime average of 3–4 pneumothoraces per patient
**May be bilateral or alternating sides
**May be bilateral or alternating sides
*'''Chylous pleural effusion (chylothorax):''' ~20% of patients; milky fluid; elevated triglycerides (>110 mg/dL)<ref name="LAMFound"/>
* Chylous pleural effusion (chylothorax): ~20% of patients; milky fluid; elevated triglycerides (>110 mg/dL)<ref name="LAMFound"/>
*'''Hemoptysis:''' Usually mild; from venule obstruction by LAM cells
* Hemoptysis: Usually mild; from venule obstruction by LAM cells
*Cough (often nonproductive)
*Cough (often nonproductive)
*Fatigue
*Fatigue
*'''Wheezing:''' ~20–25% of LAM patients have a reversible obstructive (asthma-like) component responsive to bronchodilators<ref name="LAMFound"/>
* Wheezing: ~20–25% of LAM patients have a reversible obstructive (asthma-like) component responsive to bronchodilators<ref name="LAMFound"/>
*'''Physical exam''' is often '''unremarkable''' early in disease
* Physical exam is often '''unremarkable''' early in disease
**Advanced disease: decreased breath sounds, scattered wheezes, hyperresonance
**Advanced disease: decreased breath sounds, scattered wheezes, hyperresonance
**Absent breath sounds unilaterally → pneumothorax or large effusion
**Absent breath sounds unilaterally → pneumothorax or large effusion
**Abdominal mass → lymphangioleiomyoma or hemorrhaging AML
**Abdominal mass → lymphangioleiomyoma or hemorrhaging AML
**Signs of tuberous sclerosis: facial angiofibromas, ungual fibromas, shagreen patches, hypomelanotic macules, cortical tubers
**Signs of tuberous sclerosis: facial angiofibromas, ungual fibromas, shagreen patches, hypomelanotic macules, cortical tubers
*'''ED red flags suggesting LAM in a previously undiagnosed patient:'''
* ED red flags suggesting LAM in a previously undiagnosed patient:
**Young woman with '''recurrent''' spontaneous pneumothorax (especially bilateral or alternating)
**Young woman with '''recurrent''' spontaneous pneumothorax (especially bilateral or alternating)
**Spontaneous pneumothorax in a woman with known tuberous sclerosis
**Spontaneous pneumothorax in a woman with known tuberous sclerosis
**'''Chylous''' (milky) pleural effusion in a young woman
** Chylous (milky) pleural effusion in a young woman
**Diffuse bilateral cysts found incidentally on chest CT performed for other reasons
**Diffuse bilateral cysts found incidentally on chest CT performed for other reasons
**Retroperitoneal hemorrhage from ruptured renal AML
**Retroperitoneal hemorrhage from ruptured renal AML
Line 49: Line 49:
*Lymphocytic interstitial pneumonia (LIP — cysts with ground-glass opacities; associated with [[Sjögren syndrome]] and [[HIV]])
*Lymphocytic interstitial pneumonia (LIP — cysts with ground-glass opacities; associated with [[Sjögren syndrome]] and [[HIV]])
*Birt-Hogg-Dubé syndrome (autosomal dominant; cysts predominantly '''basilar and medial'''; renal tumors are chromophobe or oncocytoma, not AML; skin fibrofolliculomas)
*Birt-Hogg-Dubé syndrome (autosomal dominant; cysts predominantly '''basilar and medial'''; renal tumors are chromophobe or oncocytoma, not AML; skin fibrofolliculomas)
*'''Emphysema''' ([[COPD]]) — older, smoker; centrilobular distribution; no true thin walls
* Emphysema ([[COPD]]) — older, smoker; centrilobular distribution; no true thin walls
*[[Amyloidosis]] (rare cystic form)
*[[Amyloidosis]] (rare cystic form)
*Light-chain deposition disease
*Light-chain deposition disease
Line 65: Line 65:
*Metastatic disease with cystic lung change (rare)
*Metastatic disease with cystic lung change (rare)


{{SOB DDX}}
{{Pulmonary fibrosis differential}}
{{SOB DDX}}
{{SOB DDX}}


Line 72: Line 76:
*CBC, [[basic metabolic panel]], lactate
*CBC, [[basic metabolic panel]], lactate
*ABG/VBG: hypoxemia in advanced disease or acute pneumothorax
*ABG/VBG: hypoxemia in advanced disease or acute pneumothorax
*'''Pleural fluid analysis''' if thoracentesis performed: '''chylous effusion''' — milky/turbid; '''triglycerides >110 mg/dL''' is diagnostic of chylothorax; '''cholesterol/triglyceride ratio <1''' distinguishes chyle from pseudochylothorax; lymphocyte-predominant<ref name="StatPearls"/>
* Pleural fluid analysis if thoracentesis performed: '''chylous effusion''' — milky/turbid; '''triglycerides >110 mg/dL''' is diagnostic of chylothorax; '''cholesterol/triglyceride ratio <1''' distinguishes chyle from pseudochylothorax; lymphocyte-predominant<ref name="StatPearls"/>
*'''Serum VEGF-D (vascular endothelial growth factor-D):''' Not an ED test, but understand its role — '''≥800 pg/mL is 100% specific''' for LAM in the setting of compatible cystic lung disease on CT; eliminates need for biopsy in most cases; low levels (<800 pg/mL) do '''not''' exclude LAM (high false-negative rate)<ref name="StatPearls"/>
* Serum VEGF-D (vascular endothelial growth factor-D): Not an ED test, but understand its role — '''≥800 pg/mL is 100% specific''' for LAM in the setting of compatible cystic lung disease on CT; eliminates need for biopsy in most cases; low levels (<800 pg/mL) do '''not''' exclude LAM (high false-negative rate)<ref name="StatPearls"/>
*If renal AML suspected (flank pain, hematuria, retroperitoneal hemorrhage): hemoglobin/hematocrit, type and screen, renal function, urinalysis
*If renal AML suspected (flank pain, hematuria, retroperitoneal hemorrhage): hemoglobin/hematocrit, type and screen, renal function, urinalysis


Line 84: Line 88:
*Pneumothorax
*Pneumothorax
*Pleural effusion
*Pleural effusion
*'''Preserved or increased lung volumes despite diffuse interstitial changes''' is a key clue (most ILDs cause volume loss; LAM causes hyperinflation from air trapping)
* Preserved or increased lung volumes despite diffuse interstitial changes is a key clue (most ILDs cause volume loss; LAM causes hyperinflation from air trapping)


''HRCT — the key diagnostic imaging study:''
''HRCT — the key diagnostic imaging study:''
*'''Diffuse, bilateral, round or ovoid, thin-walled cysts''' distributed uniformly throughout both lungs — the hallmark finding<ref name="StatPearls"/>
* Diffuse, bilateral, round or ovoid, thin-walled cysts distributed uniformly throughout both lungs — the hallmark finding<ref name="StatPearls"/>
*Cysts are typically '''2–5 mm''' but can range from 1 mm to 30 mm
*Cysts are typically '''2–5 mm''' but can range from 1 mm to 30 mm
*'''No zonal predominance''' (cysts affect upper, middle, and lower zones equally) — distinguishes from Langerhans cell histiocytosis (upper-zone predominant, spares bases) and Birt-Hogg-Dubé (basilar/medial)
* No zonal predominance (cysts affect upper, middle, and lower zones equally) — distinguishes from Langerhans cell histiocytosis (upper-zone predominant, spares bases) and Birt-Hogg-Dubé (basilar/medial)
*Intervening lung parenchyma appears '''normal''' (no ground-glass opacities, nodules, or consolidation)
*Intervening lung parenchyma appears '''normal''' (no ground-glass opacities, nodules, or consolidation)
*Ground-glass opacities suggest alternative or superimposed diagnosis
*Ground-glass opacities suggest alternative or superimposed diagnosis
*May also show: pneumothorax, pleural effusion, mediastinal/hilar lymphadenopathy, pericardial effusion
*May also show: pneumothorax, pleural effusion, mediastinal/hilar lymphadenopathy, pericardial effusion
*'''HRCT alone is NOT sufficient for definitive diagnosis''' per ATS/JRS 2017 guidelines — requires additional confirmatory features (see Diagnosis below)<ref name="ATS2017">Gupta N, et al. Lymphangioleiomyomatosis diagnosis and management: HRCT, transbronchial lung biopsy, and pleural disease management. An official ATS/JRS clinical practice guideline. ''Am J Respir Crit Care Med''. 2017;196(10):1337-1348.</ref>
* HRCT alone is NOT sufficient for definitive diagnosis per ATS/JRS 2017 guidelines — requires additional confirmatory features (see Diagnosis below)<ref name="ATS2017">Gupta N, et al. Lymphangioleiomyomatosis diagnosis and management: HRCT, transbronchial lung biopsy, and pleural disease management. An official ATS/JRS clinical practice guideline. ''Am J Respir Crit Care Med''. 2017;196(10):1337-1348.</ref>


''CT abdomen/pelvis (coordinate with inpatient/outpatient team):''
''CT abdomen/pelvis (coordinate with inpatient/outpatient team):''
Line 102: Line 106:


'''Pulmonary function tests''' (outpatient — understand the pattern):
'''Pulmonary function tests''' (outpatient — understand the pattern):
*'''Obstructive''' or '''mixed obstructive-restrictive''' pattern (unlike most ILDs which are purely restrictive)<ref name="StatPearls"/>
* Obstructive or '''mixed obstructive-restrictive''' pattern (unlike most ILDs which are purely restrictive)<ref name="StatPearls"/>
*Reduced FEV1, reduced FEV1/FVC ratio
*Reduced FEV1, reduced FEV1/FVC ratio
*Reduced DLCO (often the earliest abnormality)
*Reduced DLCO (often the earliest abnormality)
Line 109: Line 113:


===Diagnosis===
===Diagnosis===
*'''Definitive diagnosis of LAM''' can be made '''without biopsy''' when characteristic cystic lung disease on HRCT is present '''plus''' any ONE of the following:<ref name="StatPearls"/>
* Definitive diagnosis of LAM can be made '''without biopsy''' when characteristic cystic lung disease on HRCT is present '''plus''' any ONE of the following:<ref name="StatPearls"/>
**(1) Diagnosis of tuberous sclerosis
**(1) Diagnosis of tuberous sclerosis
**(2) Serum VEGF-D '''≥800 pg/mL'''
**(2) Serum VEGF-D '''≥800 pg/mL'''
Line 115: Line 119:
**(4) Lymphangioleiomyoma
**(4) Lymphangioleiomyoma
**(5) Chylous effusion (pleural or ascitic)
**(5) Chylous effusion (pleural or ascitic)
*'''HRCT findings alone are insufficient''' for definitive diagnosis (per ATS/JRS 2017) due to overlap with other cystic lung diseases; requires confirmatory clinical, radiologic, or serologic feature<ref name="ATS2017"/>
* HRCT findings alone are insufficient for definitive diagnosis (per ATS/JRS 2017) due to overlap with other cystic lung diseases; requires confirmatory clinical, radiologic, or serologic feature<ref name="ATS2017"/>
*If no confirmatory features: consider transbronchial lung biopsy (HMB-45 staining is highly specific) or surgical lung biopsy<ref name="ATS2017"/>
*If no confirmatory features: consider transbronchial lung biopsy (HMB-45 staining is highly specific) or surgical lung biopsy<ref name="ATS2017"/>
*'''In the ED:''' The goal is not to definitively diagnose LAM, but to recognize the pattern (young woman + recurrent pneumothorax + diffuse cysts on CT) and ensure appropriate referral
* In the ED: The goal is not to definitively diagnose LAM, but to recognize the pattern (young woman + recurrent pneumothorax + diffuse cysts on CT) and ensure appropriate referral


==Management==
==Management==
Line 124: Line 128:
'''1. Pneumothorax management:'''
'''1. Pneumothorax management:'''
*Treat per standard [[pneumothorax]] protocols: observation for small pneumothorax without respiratory distress; '''chest tube thoracostomy''' (pigtail or surgical) for symptomatic or large pneumothorax<ref name="LAMFound"/>
*Treat per standard [[pneumothorax]] protocols: observation for small pneumothorax without respiratory distress; '''chest tube thoracostomy''' (pigtail or surgical) for symptomatic or large pneumothorax<ref name="LAMFound"/>
*'''Critical LAM-specific point:''' Recurrence rate is >70% with conservative management alone; ATS/JRS guidelines recommend '''pleurodesis after the FIRST pneumothorax''' rather than waiting for recurrence<ref name="ATS2017"/>
* Critical LAM-specific point: Recurrence rate is >70% with conservative management alone; ATS/JRS guidelines recommend '''pleurodesis after the FIRST pneumothorax''' rather than waiting for recurrence<ref name="ATS2017"/>
*VATS-guided mechanical abrasion is the preferred initial pleurodesis modality; chemical pleurodesis (talc) is reserved for recurrence after initial pleurodesis<ref name="LAMFound"/>
*VATS-guided mechanical abrasion is the preferred initial pleurodesis modality; chemical pleurodesis (talc) is reserved for recurrence after initial pleurodesis<ref name="LAMFound"/>
*'''Prior pleurodesis is NOT a contraindication for future lung transplantation''' (ATS/JRS 2017) — this is critical to know, as outdated teaching suggested otherwise and may cause clinicians to delay pleurodesis<ref name="ATS2017"/>
* Prior pleurodesis is NOT a contraindication for future lung transplantation (ATS/JRS 2017) — this is critical to know, as outdated teaching suggested otherwise and may cause clinicians to delay pleurodesis<ref name="ATS2017"/>
*Consult thoracic surgery early for patients with known or suspected LAM and pneumothorax
*Consult thoracic surgery early for patients with known or suspected LAM and pneumothorax
*'''Sirolimus note:''' sirolimus impairs wound healing and may need to be withheld during active air leak management — discuss with the patient's pulmonologist<ref name="LAMFound"/>
* Sirolimus note: sirolimus impairs wound healing and may need to be withheld during active air leak management — discuss with the patient's pulmonologist<ref name="LAMFound"/>


'''2. Chylous effusion:'''
'''2. Chylous effusion:'''
*'''Thoracentesis''' for symptomatic chylothorax — send fluid for triglycerides, cell count, LDH, protein, cultures
* Thoracentesis for symptomatic chylothorax — send fluid for triglycerides, cell count, LDH, protein, cultures
*Chylous effusions respond well to '''sirolimus''' (first-line medical treatment rather than invasive procedures)<ref name="LAMFound"/>
*Chylous effusions respond well to '''sirolimus''' (first-line medical treatment rather than invasive procedures)<ref name="LAMFound"/>
*Avoid repeated thoracentesis when possible (nutritional depletion from chyle loss; consider dietary modification with medium-chain triglycerides)
*Avoid repeated thoracentesis when possible (nutritional depletion from chyle loss; consider dietary modification with medium-chain triglycerides)
Line 146: Line 150:


'''5. Disease-modifying therapy (outpatient — coordinate with pulmonology):'''
'''5. Disease-modifying therapy (outpatient — coordinate with pulmonology):'''
*'''Sirolimus (rapamycin)''' — '''the only FDA-approved treatment''' for LAM; mTORC1 inhibitor<ref name="MILES"/>
* Sirolimus (rapamycin) — '''the only FDA-approved treatment''' for LAM; mTORC1 inhibitor<ref name="MILES"/>
**MILES trial: stabilized FEV1 decline (placebo lost 12 mL/month vs. sirolimus gained 1 mL/month; p<0.001); reduced serum VEGF-D; improved quality of life<ref name="MILES"/>
**MILES trial: stabilized FEV1 decline (placebo lost 12 mL/month vs. sirolimus gained 1 mL/month; p<0.001); reduced serum VEGF-D; improved quality of life<ref name="MILES"/>
**Treatment is '''suppressive, not curative''' — long-term continuous therapy required; disease progresses again upon discontinuation<ref name="LAMFound"/>
**Treatment is '''suppressive, not curative''' — long-term continuous therapy required; disease progresses again upon discontinuation<ref name="LAMFound"/>
Line 152: Line 156:
**Indications: FEV1 <70% predicted, FEV1 decline ≥90 mL/year, refractory chylous effusions, AML ≥4 cm, significant disease burden<ref name="LAMFound"/>
**Indications: FEV1 <70% predicted, FEV1 decline ≥90 mL/year, refractory chylous effusions, AML ≥4 cm, significant disease burden<ref name="LAMFound"/>
**Side effects: oral mucositis (most common), hyperlipidemia, diarrhea, peripheral edema, delayed wound healing, increased infection risk, ovarian cysts
**Side effects: oral mucositis (most common), hyperlipidemia, diarrhea, peripheral edema, delayed wound healing, increased infection risk, ovarian cysts
*'''Everolimus:''' Alternative mTOR inhibitor; FDA-approved for TSC-associated AML and subependymal giant cell astrocytoma; similar efficacy and side effect profile
* Everolimus: Alternative mTOR inhibitor; FDA-approved for TSC-associated AML and subependymal giant cell astrocytoma; similar efficacy and side effect profile
*'''Avoid estrogen-containing medications:''' oral contraceptive pills, hormone replacement therapy — may accelerate disease<ref name="StatPearls"/>
* Avoid estrogen-containing medications: oral contraceptive pills, hormone replacement therapy — may accelerate disease<ref name="StatPearls"/>
*Lung transplantation for end-stage disease (FEV1 <30% predicted or severe functional limitation); note: LAM can recur in transplanted lung<ref name="StatPearls"/>
*Lung transplantation for end-stage disease (FEV1 <30% predicted or severe functional limitation); note: LAM can recur in transplanted lung<ref name="StatPearls"/>


==Disposition==
==Disposition==
*'''Admit:'''
* Admit:
**Pneumothorax requiring chest tube (strongly consider thoracic surgery consultation for pleurodesis discussion given high recurrence rate)
**Pneumothorax requiring chest tube (strongly consider thoracic surgery consultation for pleurodesis discussion given high recurrence rate)
**Significant chylothorax with respiratory compromise
**Significant chylothorax with respiratory compromise
Line 163: Line 167:
**Respiratory failure or new/increased O2 requirement
**Respiratory failure or new/increased O2 requirement
**Hemodynamic instability
**Hemodynamic instability
*'''Discharge with close follow-up:'''
* Discharge with close follow-up:
**Small, stable pneumothorax managed with observation in a patient with adequate oxygenation and close outpatient follow-up assured
**Small, stable pneumothorax managed with observation in a patient with adequate oxygenation and close outpatient follow-up assured
**Known LAM patient with mild exacerbation of dyspnea at baseline, stable vitals, and no evidence of pneumothorax or effusion
**Known LAM patient with mild exacerbation of dyspnea at baseline, stable vitals, and no evidence of pneumothorax or effusion
**'''Suspected new LAM diagnosis''' (young woman with characteristic CT findings): ensure urgent outpatient pulmonology referral (ideally to a center with LAM expertise)
** Suspected new LAM diagnosis (young woman with characteristic CT findings): ensure urgent outpatient pulmonology referral (ideally to a center with LAM expertise)
*'''Discharge counseling:'''
* Discharge counseling:
**Return immediately for sudden chest pain, worsening dyspnea, or hemoptysis (pneumothorax recurrence)
**Return immediately for sudden chest pain, worsening dyspnea, or hemoptysis (pneumothorax recurrence)
**Avoid estrogen-containing contraceptives and hormone replacement
**Avoid estrogen-containing contraceptives and hormone replacement
**'''Air travel:''' associated with increased pneumothorax risk — discuss with pulmonologist before flying<ref name="ERS2010"/>
** Air travel: associated with increased pneumothorax risk — discuss with pulmonologist before flying<ref name="ERS2010"/>
**'''Pregnancy:''' may accelerate LAM progression; requires pre-pregnancy counseling with a LAM specialist<ref name="StatPearls"/>
** Pregnancy: may accelerate LAM progression; requires pre-pregnancy counseling with a LAM specialist<ref name="StatPearls"/>
**Scuba diving is '''contraindicated''' (pneumothorax risk)
**Scuba diving is '''contraindicated''' (pneumothorax risk)
**Do not discontinue sirolimus without discussing with pulmonologist
**Do not discontinue sirolimus without discussing with pulmonologist

Revision as of 14:41, 19 March 2026

Background

  • Lymphangioleiomyomatosis (LAM) is a rare, progressive, low-grade neoplastic lung disease characterized by infiltration of abnormal smooth muscle-like cells (LAM cells) into the lung parenchyma, lymphatics, and blood vessels, resulting in diffuse thin-walled cystic destruction of both lungs.[1] It almost exclusively affects women of childbearing age (mean diagnosis ~35 years).
  • LAM cells harbor mutations in tuberous sclerosis complex (TSC) genes causing constitutive activation of the mTOR pathway.[2] ED physicians will most commonly encounter LAM patients presenting with recurrent spontaneous pneumothorax, chylous pleural effusion, or progressive dyspnea — and the diagnosis may not yet be established.
  • LAM occurs in two forms:[1]
    • Sporadic LAM (S-LAM): Somatic TSC2 mutations; ~3.4–7.8 per million women; no family inheritance
    • TSC-associated LAM (TSC-LAM): 30–40% of women with tuberous sclerosis develop LAM; autosomal dominant TSC1 or TSC2 germline mutations
  • LAM cells are neoplastic smooth muscle-like cells that express smooth muscle actin, HMB-45 (melanocytic marker — key for pathologic diagnosis), and estrogen/progesterone receptors[3]
  • Estrogen dependence: LAM almost exclusively affects premenopausal women; may accelerate during pregnancy and with exogenous estrogen; decelerates after menopause[1]
  • Pathogenesis: TSC gene mutations → loss of hamartin/tuberin tumor suppressor complex → constitutive mTORC1 activation → uncontrolled cell proliferation, lymphangiogenesis, and cystic lung destruction[2]
  • LAM cells metastasize via the lymphatics (LAM is considered a low-grade metastasizing neoplasm with likely uterine origin)[2]
  • Proliferation of LAM cells obstructs bronchioles (→ air trapping, bullae, pneumothorax), lymphatics (→ chylous effusions), and venules (→ hemoptysis)[4]
  • Extrapulmonary manifestations:
    • Renal angiomyolipomas (AML): Present in ~30–40% of S-LAM and ~80% of TSC-LAM; benign fat-containing tumors; may hemorrhage (especially >4 cm)[3]
    • Lymphangioleiomyomas: Cystic masses of the axial lymphatics; abdominopelvic lymphadenopathy
    • Chylous effusions: Chylothorax (~20%) and/or chylous ascites from lymphatic obstruction[5]
    • Increased frequency of meningiomas[3]
  • Epidemiology: ~3.4–7.8 per million women (sporadic LAM); prevalence likely underestimated due to delayed diagnosis (average 5–6 years from symptom onset)[1]
  • FEV1 declines at ~75–118 mL/year in untreated patients[6]
  • >90% 10-year survival with modern management[7]

Clinical Features

  • Progressive exertional dyspnea — the most common symptom; insidious onset; often attributed to asthma or deconditioning for years before diagnosis[1]
  • Recurrent spontaneous pneumothorax:[2]
    • Occurs in ~66% of LAM patients during their lifetime
    • Presenting manifestation in ~25% of patients — this is often how LAM is first diagnosed
    • Recurrence rate >70% if managed conservatively (observation/aspiration alone)
    • Lifetime average of 3–4 pneumothoraces per patient
    • May be bilateral or alternating sides
  • Chylous pleural effusion (chylothorax): ~20% of patients; milky fluid; elevated triglycerides (>110 mg/dL)[5]
  • Hemoptysis: Usually mild; from venule obstruction by LAM cells
  • Cough (often nonproductive)
  • Fatigue
  • Wheezing: ~20–25% of LAM patients have a reversible obstructive (asthma-like) component responsive to bronchodilators[5]
  • Physical exam is often unremarkable early in disease
    • Advanced disease: decreased breath sounds, scattered wheezes, hyperresonance
    • Absent breath sounds unilaterally → pneumothorax or large effusion
    • Abdominal mass → lymphangioleiomyoma or hemorrhaging AML
    • Signs of tuberous sclerosis: facial angiofibromas, ungual fibromas, shagreen patches, hypomelanotic macules, cortical tubers
  • ED red flags suggesting LAM in a previously undiagnosed patient:
    • Young woman with recurrent spontaneous pneumothorax (especially bilateral or alternating)
    • Spontaneous pneumothorax in a woman with known tuberous sclerosis
    • Chylous (milky) pleural effusion in a young woman
    • Diffuse bilateral cysts found incidentally on chest CT performed for other reasons
    • Retroperitoneal hemorrhage from ruptured renal AML

Differential Diagnosis

Diffuse cystic lung diseases (the primary radiologic differential):[2]

  • Pulmonary Langerhans cell histiocytosis (cysts + nodules; spares costophrenic angles; smoker; irregularly shaped cysts)
  • Lymphocytic interstitial pneumonia (LIP — cysts with ground-glass opacities; associated with Sjögren syndrome and HIV)
  • Birt-Hogg-Dubé syndrome (autosomal dominant; cysts predominantly basilar and medial; renal tumors are chromophobe or oncocytoma, not AML; skin fibrofolliculomas)
  • Emphysema (COPD) — older, smoker; centrilobular distribution; no true thin walls
  • Amyloidosis (rare cystic form)
  • Light-chain deposition disease

Other causes of recurrent pneumothorax in young women:

Other:

Acute dyspnea

Emergent

Non-Emergent


Pulmonary Fibrosis

Acute dyspnea

Emergent

Non-Emergent

Evaluation

Workup

Laboratory (ED):

  • CBC, basic metabolic panel, lactate
  • ABG/VBG: hypoxemia in advanced disease or acute pneumothorax
  • Pleural fluid analysis if thoracentesis performed: chylous effusion — milky/turbid; triglycerides >110 mg/dL is diagnostic of chylothorax; cholesterol/triglyceride ratio <1 distinguishes chyle from pseudochylothorax; lymphocyte-predominant[1]
  • Serum VEGF-D (vascular endothelial growth factor-D): Not an ED test, but understand its role — ≥800 pg/mL is 100% specific for LAM in the setting of compatible cystic lung disease on CT; eliminates need for biopsy in most cases; low levels (<800 pg/mL) do not exclude LAM (high false-negative rate)[1]
  • If renal AML suspected (flank pain, hematuria, retroperitoneal hemorrhage): hemoglobin/hematocrit, type and screen, renal function, urinalysis

Imaging:

Chest X-ray:

  • May be normal early in disease
  • Increased lung volumes (hyperinflation) — unlike most ILDs which cause volume loss
  • Reticulonodular pattern
  • Pneumothorax
  • Pleural effusion
  • Preserved or increased lung volumes despite diffuse interstitial changes is a key clue (most ILDs cause volume loss; LAM causes hyperinflation from air trapping)

HRCT — the key diagnostic imaging study:

  • Diffuse, bilateral, round or ovoid, thin-walled cysts distributed uniformly throughout both lungs — the hallmark finding[1]
  • Cysts are typically 2–5 mm but can range from 1 mm to 30 mm
  • No zonal predominance (cysts affect upper, middle, and lower zones equally) — distinguishes from Langerhans cell histiocytosis (upper-zone predominant, spares bases) and Birt-Hogg-Dubé (basilar/medial)
  • Intervening lung parenchyma appears normal (no ground-glass opacities, nodules, or consolidation)
  • Ground-glass opacities suggest alternative or superimposed diagnosis
  • May also show: pneumothorax, pleural effusion, mediastinal/hilar lymphadenopathy, pericardial effusion
  • HRCT alone is NOT sufficient for definitive diagnosis per ATS/JRS 2017 guidelines — requires additional confirmatory features (see Diagnosis below)[8]

CT abdomen/pelvis (coordinate with inpatient/outpatient team):

  • Renal angiomyolipomas: fat-containing renal masses (classically fat-density on CT); may be bilateral and multiple; risk of hemorrhage if >4 cm
  • Retroperitoneal lymphangioleiomyomas
  • Lymphadenopathy
  • Chylous ascites

Pulmonary function tests (outpatient — understand the pattern):

  • Obstructive or mixed obstructive-restrictive pattern (unlike most ILDs which are purely restrictive)[1]
  • Reduced FEV1, reduced FEV1/FVC ratio
  • Reduced DLCO (often the earliest abnormality)
  • Increased residual volume (air trapping)
  • ~20–25% have bronchodilator responsiveness[5]

Diagnosis

  • Definitive diagnosis of LAM can be made without biopsy when characteristic cystic lung disease on HRCT is present plus any ONE of the following:[1]
    • (1) Diagnosis of tuberous sclerosis
    • (2) Serum VEGF-D ≥800 pg/mL
    • (3) Renal angiomyolipoma (confirmed by imaging)
    • (4) Lymphangioleiomyoma
    • (5) Chylous effusion (pleural or ascitic)
  • HRCT findings alone are insufficient for definitive diagnosis (per ATS/JRS 2017) due to overlap with other cystic lung diseases; requires confirmatory clinical, radiologic, or serologic feature[8]
  • If no confirmatory features: consider transbronchial lung biopsy (HMB-45 staining is highly specific) or surgical lung biopsy[8]
  • In the ED: The goal is not to definitively diagnose LAM, but to recognize the pattern (young woman + recurrent pneumothorax + diffuse cysts on CT) and ensure appropriate referral

Management

ED management is primarily supportive and complication-directed:

1. Pneumothorax management:

  • Treat per standard pneumothorax protocols: observation for small pneumothorax without respiratory distress; chest tube thoracostomy (pigtail or surgical) for symptomatic or large pneumothorax[5]
  • Critical LAM-specific point: Recurrence rate is >70% with conservative management alone; ATS/JRS guidelines recommend pleurodesis after the FIRST pneumothorax rather than waiting for recurrence[8]
  • VATS-guided mechanical abrasion is the preferred initial pleurodesis modality; chemical pleurodesis (talc) is reserved for recurrence after initial pleurodesis[5]
  • Prior pleurodesis is NOT a contraindication for future lung transplantation (ATS/JRS 2017) — this is critical to know, as outdated teaching suggested otherwise and may cause clinicians to delay pleurodesis[8]
  • Consult thoracic surgery early for patients with known or suspected LAM and pneumothorax
  • Sirolimus note: sirolimus impairs wound healing and may need to be withheld during active air leak management — discuss with the patient's pulmonologist[5]

2. Chylous effusion:

  • Thoracentesis for symptomatic chylothorax — send fluid for triglycerides, cell count, LDH, protein, cultures
  • Chylous effusions respond well to sirolimus (first-line medical treatment rather than invasive procedures)[5]
  • Avoid repeated thoracentesis when possible (nutritional depletion from chyle loss; consider dietary modification with medium-chain triglycerides)
  • Pleurodesis or thoracic duct ligation for refractory cases

3. Renal AML hemorrhage:

  • Acute retroperitoneal hemorrhage from ruptured AML: hemodynamic resuscitation, emergent CT angiography, selective arterial embolization is preferred over nephrectomy (nephron-sparing approach)[3]
  • AML >4 cm: higher hemorrhage risk; elective embolization or mTOR inhibitor therapy to shrink tumor

4. Respiratory support:

  • Supplemental O2 to maintain SpO2 ≥90%[5]
  • Bronchodilators (albuterol) — may benefit the ~20–25% with reversible airway obstruction; reasonable to trial in any symptomatic LAM patient[5]
  • Non-invasive ventilation or intubation for respiratory failure

5. Disease-modifying therapy (outpatient — coordinate with pulmonology):

  • Sirolimus (rapamycin) — the only FDA-approved treatment for LAM; mTORC1 inhibitor[6]
    • MILES trial: stabilized FEV1 decline (placebo lost 12 mL/month vs. sirolimus gained 1 mL/month; p<0.001); reduced serum VEGF-D; improved quality of life[6]
    • Treatment is suppressive, not curative — long-term continuous therapy required; disease progresses again upon discontinuation[5]
    • Sirolimus also reduces pneumothorax recurrence by ~80% and is first-line for chylous effusions and AML[9]
    • Indications: FEV1 <70% predicted, FEV1 decline ≥90 mL/year, refractory chylous effusions, AML ≥4 cm, significant disease burden[5]
    • Side effects: oral mucositis (most common), hyperlipidemia, diarrhea, peripheral edema, delayed wound healing, increased infection risk, ovarian cysts
  • Everolimus: Alternative mTOR inhibitor; FDA-approved for TSC-associated AML and subependymal giant cell astrocytoma; similar efficacy and side effect profile
  • Avoid estrogen-containing medications: oral contraceptive pills, hormone replacement therapy — may accelerate disease[1]
  • Lung transplantation for end-stage disease (FEV1 <30% predicted or severe functional limitation); note: LAM can recur in transplanted lung[1]

Disposition

  • Admit:
    • Pneumothorax requiring chest tube (strongly consider thoracic surgery consultation for pleurodesis discussion given high recurrence rate)
    • Significant chylothorax with respiratory compromise
    • Acute retroperitoneal hemorrhage from renal AML
    • Respiratory failure or new/increased O2 requirement
    • Hemodynamic instability
  • Discharge with close follow-up:
    • Small, stable pneumothorax managed with observation in a patient with adequate oxygenation and close outpatient follow-up assured
    • Known LAM patient with mild exacerbation of dyspnea at baseline, stable vitals, and no evidence of pneumothorax or effusion
    • Suspected new LAM diagnosis (young woman with characteristic CT findings): ensure urgent outpatient pulmonology referral (ideally to a center with LAM expertise)
  • Discharge counseling:
    • Return immediately for sudden chest pain, worsening dyspnea, or hemoptysis (pneumothorax recurrence)
    • Avoid estrogen-containing contraceptives and hormone replacement
    • Air travel: associated with increased pneumothorax risk — discuss with pulmonologist before flying[3]
    • Pregnancy: may accelerate LAM progression; requires pre-pregnancy counseling with a LAM specialist[1]
    • Scuba diving is contraindicated (pneumothorax risk)
    • Do not discontinue sirolimus without discussing with pulmonologist
    • The LAM Foundation (www.thelamfoundation.org) is an excellent patient resource

See Also

External Links

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Lymphangioleiomyomatosis. StatPearls. NCBI Bookshelf. Updated June 2023.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 McCormack FX, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 Johnson SR, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14-26.
  4. ↑ Lymphangioleiomyomatosis. Medscape/eMedicine. Updated 2024.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 LAM Management. The LAM Foundation. Updated October 2023.
  6. ↑ 6.0 6.1 6.2 McCormack FX, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595-1606.
  7. ↑ Lymphangioleiomyomatosis (LAM). Cleveland Clinic. Updated December 2025.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Gupta N, et al. Lymphangioleiomyomatosis diagnosis and management: HRCT, transbronchial lung biopsy, and pleural disease management. An official ATS/JRS clinical practice guideline. Am J Respir Crit Care Med. 2017;196(10):1337-1348.
  9. ↑ Cheng C, et al. Sirolimus reduces the risk of pneumothorax recurrence in patients with LAM. Orphanet J Rare Dis. 2022;17(1):257.
Retrieved from "https://www.wikem.org/w/index.php?title=Lymphangioleiomyomatosis&oldid=386215"